Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.53 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232433 | 1.00 | S1PR5 (0.53) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL585358 | 1.00 | S1PR5 (0.53) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL6232439 | 1.00 | S1PR5 (0.53) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL9112639 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL585359 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL8229357 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL9112633 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL19064205 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL5119476 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL19121611 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| EP-4271676-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | Bionova Pharmaceuticals (Shanghai) Limited (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116829559-A | Carbonyl substituted diazaspiro compounds and uses thereof | 烨辉医药科技(上海)有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023098876-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS (SHANGHAI) LIMITED (CN) | 2023-06-08 | — | — | WO | disclosed |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-08-23 | — | — | US | disclosed |
| US-9944613-B2 | Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2284171-A1 | Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types | Targacept, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2257549-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | Targacept Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100081683-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGCEPT INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2009111550-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | TARGACEPT, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-2094703-A1 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | Targacept, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008057938-A1 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | S1PR5 3584/4885S1PR1 3773/4885FUCA1 4669/4885 |
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | MMP1, MMP8, MMP9 | S1PR5 2901/4885S1PR1 1667/4885FUCA1 658/4885 |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | S1PR5 2786/4885S1PR1 2867/4885FUCA1 166/4885 |
| US-20100081683-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA7, CHRNE, CHRNA2 | S1PR5 1207/4885S1PR1 1064/4885FUCA1 2159/4885 |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | S1PR5 2786/4885S1PR1 2867/4885FUCA1 166/4885 |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | S1PR5 2786/4885S1PR1 2867/4885FUCA1 166/4885 |
| US-20100173932-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA4, CHRNA2, CHRNE | S1PR5 1544/4885S1PR1 1830/4885FUCA1 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.